Trial results cite most cost effective treatment for enteric and/or respiratory infections

BASEL - Novartis Animal Health has announced that results from seven recent field trials around the world showed that Denagard® / Tiamutin® provides the most cost-effective solution when compared head-to-head with tylosin and lincomycin – increasing margins up to €23.60 ($29.50) per pig sold in some cases.
calendar icon 15 November 2006
clock icon 3 minute read
Novartis Animal Health

The field trials, conducted in the UK, Germany, Japan, Brazil, China and Thailand, compared Denagard / Tiamutin with lincomycin and tylosin in terms of cost benefit when treating a broad range of diseases, including ileitis and Porcine Respiratory Disease Complex (PRDC). In each trial, Denagard / Tiamutin provided a better return on investment for producers, while also effectively treating the disease.

“These trials show that Denagard / Tiamutin offered clear benefits over parallel treatments in these commercial units with mixed enteric and/or respiratory infections,” said Dr. Jill Thomson, Veterinary Centre Manager, Scottish Agricultural College, Edinburgh, UK. “Many swine producers are faced with a number of endemic diseases that erode their profits. Farmers should be pro-active with their veterinary diagnostic involvement, treatment and control regimes, and look at evidence when choosing a health solution. Effective disease control strategies as advised by the veterinary advisor to the unit, including targeted treatment, good management and health planning are vital to protect and improve producer profits.”

The field trials were conducted on different types of farms throughout different markets around the world to represent a true cross section of experiences. All seven trials were led by independent veterinary specialists.

For example, a trial carried out in Germany evaluated the efficacy and cost benefit of Denagard / Tiamutin 45% Water Soluble Granule compared with soluble tylosin against ileitis. The pigs treated with Denagard / Tiamutin demonstrated a cost benefit of €4.79 per pig sold due to the efficacy against ileitis resulting in improved performance, shorter fattening times and higher weight gains per sold pig.

“Denagard / Tiamutin has been helping farmers effectively treat enteric and respiratory diseases in swine for over 25 years,” said Dr. Simon Wheeler, Head of Professional Relations at Novartis Animal Health. “This new data proves what we have long believed to be true: Denagard / Tiamutin is not only effective against costly diseases but it also provides real value to pig farmers around the world.”

Summary of Trial Results

To read the Summary of Trial Results in either US$ or €, see below:

US$ format
Euro's (PDF)

ThePigSite News Desk

© 2000 - 2023 - Global Ag Media. All Rights Reserved | No part of this site may be reproduced without permission.